US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Enliven Treateutics

20.74

-0.6300-2.95%

Post-market: 20.740.00000.00%16:04 EDT

Volume:663.45K

Turnover:13.91M

Market Cap:1.02B

PE:-10.73

High:22.52

Open:21.78

Low:20.04

Close:21.37

Loading ...

Overview Company News Filings

Enliven Therapeutics CEO Samuel Kintz Reports Disposal of Common Shares

Enliven Therapeutics: Buy Rating Backed by Promising ELVN-001 Developments in CML Treatment

Enliven Therapeutics Inc : Mizuho Raises Target Price to $41 From $39

THOMSON REUTERS

CFO Benjamin Hohl Reports Disposal of Common Shares of Enliven Therapeutics Inc

Enliven Therapeutics’ ELVN-001: Promising Efficacy and Safety in Late Line CML Market

Enliven Therapeutics Inc. to Participate in TD Cowen's 6th Annual Oncology Innovation Summit

Enliven Therapeutics CEO Samuel Kintz Reports Disposal of Common Shares

Enliven Therapeutics Is Maintained at Buy by Jones Trading

Stock Track | Enliven Therapeutics Plummets 5.22% Following Price Target Cut

Stock Track | Enliven Therapeutics Plummets 5.22% as JonesResearch Lowers Price Target

Enliven price target lowered to $27 from $36 at JonesResearch

Enliven Therapeutics’ ELVN-001: Promising Competitor in the $3 Billion Late Line CML Market

Enliven Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $40 From $39

THOMSON REUTERS

Enliven Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Enliven Therapeutics Q1 EPS $(0.57) Misses $(0.49) Estimate

Enliven Therapeutics Q1 Income From Operations USD -31.693 Million

THOMSON REUTERS

Press Release: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Positive Buy Rating for Enliven Therapeutics Driven by Promising Phase 1 Results of ELVN-001 in CML

BRIEF-Enliven Therapeutics Says ELVN-001 Shows Favorable Safety And Tolerability Profile

Enliven Therapeutics Announces Updated Positive Data From Phase 1 Clinical Trial of Elvn-001 in Cml and Oral Presentation at the Eha 2025 Congress

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ELVN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ELVN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELVN\",,,,,undefined,":{"symbol":"ELVN","market":"US","secType":"STK","nameCN":"Enliven Treateutics","latestPrice":20.74,"timestamp":1749240000000,"preClose":21.37,"halted":0,"volume":663450,"hourTrading":{"tag":"盘后","latestPrice":20.74,"preClose":20.74,"latestTime":"16:04 EDT","volume":5434,"amount":112701.16,"timestamp":1749240244303},"delay":0,"floatShares":26570649,"shares":49069258,"eps":-1.932389,"marketStatus":"Market Closed","change":-0.63,"latestTime":"06-06 16:00:00 EDT","open":21.78,"high":22.5245,"low":20.04,"amount":13907949.055776,"amplitude":0.116261,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.932389,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"listingDate":1583985600000,"exchange":"NASDAQ","adjPreClose":21.37,"preHourTrading":{"tag":"盘前","latestPrice":21.47,"preClose":21.37,"latestTime":"09:25 EDT","volume":30,"amount":644.0999999999999,"timestamp":1749216300068},"postHourTrading":{"tag":"盘后","latestPrice":20.74,"preClose":20.74,"latestTime":"16:04 EDT","volume":5434,"amount":112701.16,"timestamp":1749240244303},"volumeRatio":1.2710792823872126,"impliedVol":0.6272,"impliedVolPercentile":0.428},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELVN\",,,,,undefined,":{"symbol":"ELVN","floatShares":26570649,"roa":"-21.36%","roe":"-31.30%","lyrEps":-1.891209,"volumeRatio":1.2710792823872126,"shares":49069258,"dividePrice":0,"high":22.5245,"amplitude":0.116261,"preClose":21.37,"low":20.04,"week52Low":13.3,"pbRate":"3.53","week52High":30.03,"institutionHeld":0,"latestPrice":20.74,"eps":-1.932389,"divideRate":0,"volume":663450,"delay":0,"ttmEps":-1.932389,"open":21.78,"prevYearClose":22.5,"prevWeekClose":17.77,"prevMonthClose":17.77,"prevQuarterClose":19.68,"fiveDayClose":17.77,"twentyDayClose":18.63,"sixtyDayClose":21.02},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ELVN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541000610","title":"Enliven Therapeutics CEO Samuel Kintz Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2541000610","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541000610?lang=en_us&edition=fundamental","pubTime":"2025-06-06 04:54","pubTimestamp":1749156868,"startTime":"0","endTime":"0","summary":"Samuel Kintz, President and CEO of Enliven Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL6ChjrF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enliven Therapeutics CEO Samuel Kintz Reports Disposal of Common Shares","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2540970983","title":"Enliven Therapeutics: Buy Rating Backed by Promising ELVN-001 Developments in CML Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2540970983","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540970983?lang=en_us&edition=fundamental","pubTime":"2025-06-04 01:35","pubTimestamp":1748972112,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Soumit Roy has maintained their bullish stance on ELVN stock, giving a Buy rating on May 29. Soumit Roy has given his Buy rati...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/enliven-therapeutics-buy-rating-backed-by-promising-elvn-001-developments-in-cml-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/enliven-therapeutics-buy-rating-backed-by-promising-elvn-001-developments-in-cml-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","ELVN"],"gpt_icon":0},{"id":"2539226348","title":"Enliven Therapeutics Inc : Mizuho Raises Target Price to $41 From $39","url":"https://stock-news.laohu8.com/highlight/detail?id=2539226348","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539226348?lang=en_us&edition=fundamental","pubTime":"2025-05-30 18:35","pubTimestamp":1748601332,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nFWN3S215L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2539299970","title":"CFO Benjamin Hohl Reports Disposal of Common Shares of Enliven Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2539299970","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539299970?lang=en_us&edition=fundamental","pubTime":"2025-05-30 05:38","pubTimestamp":1748554735,"startTime":"0","endTime":"0","summary":"Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL2WPLQB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"CFO Benjamin Hohl Reports Disposal of Common Shares of Enliven Therapeutics Inc","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2539059164","title":"Enliven Therapeutics’ ELVN-001: Promising Efficacy and Safety in Late Line CML Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2539059164","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539059164?lang=en_us&edition=fundamental","pubTime":"2025-05-29 02:25","pubTimestamp":1748456714,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Soumit Roy has maintained their bullish stance on ELVN stock, giving a Buy rating on May 15. Soumit Roy has given his Buy rati...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/enliven-therapeutics-elvn-001-promising-efficacy-and-safety-in-late-line-cml-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/enliven-therapeutics-elvn-001-promising-efficacy-and-safety-in-late-line-cml-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4007","BK4539","ELVN"],"gpt_icon":0},{"id":"2537924089","title":"Enliven Therapeutics Inc. to Participate in TD Cowen's 6th Annual Oncology Innovation Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2537924089","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537924089?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:05","pubTimestamp":1747944328,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, is set to present at TD Cowen's 6th Annual Oncology Innovation Summit on Tuesday, May 27, 2025. The presentation will take the form of a fireside chat and will offer insights from ASCO & EHA.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on May 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDL5CF2cZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2537522259","title":"Enliven Therapeutics CEO Samuel Kintz Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2537522259","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537522259?lang=en_us&edition=fundamental","pubTime":"2025-05-22 06:30","pubTimestamp":1747866630,"startTime":"0","endTime":"0","summary":"Samuel Kintz, President and CEO of Enliven Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 21, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDLbFrL2R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2536323392","title":"Enliven Therapeutics Is Maintained at Buy by Jones Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2536323392","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536323392?lang=en_us&edition=fundamental","pubTime":"2025-05-17 04:45","pubTimestamp":1747428300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ELVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 16, 2025 16:45 ET (20:45 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","LENZ"],"gpt_icon":0},{"id":"1182243756","title":"Stock Track | Enliven Therapeutics Plummets 5.22% Following Price Target Cut","url":"https://stock-news.laohu8.com/highlight/detail?id=1182243756","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182243756?lang=en_us&edition=fundamental","pubTime":"2025-05-17 03:40","pubTimestamp":1747424420,"startTime":"0","endTime":"0","summary":"Shares of Enliven Therapeutics  took a significant hit during Friday's intraday trading, plummeting 5.22% as investors reacted to a downward revision in the company's price target by a prominent research firm.JonesResearch analyst Soumit Roy adjusted the price target for Enliven from $36 to $27, representing a 25% reduction. Despite the lower target, Roy maintained a Buy rating on the stock, suggesting continued confidence in the company's long-term prospects. The revised outlook appears to have","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ELVN"],"gpt_icon":0},{"id":"1107857827","title":"Stock Track | Enliven Therapeutics Plummets 5.22% as JonesResearch Lowers Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1107857827","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107857827?lang=en_us&edition=fundamental","pubTime":"2025-05-17 03:40","pubTimestamp":1747424420,"startTime":"0","endTime":"0","summary":"Shares of Enliven Therapeutics  plummeted 5.22% during Friday's intraday trading session, reflecting investor concerns following an analyst's downward revision of the company's price target.The significant drop in share price came after JonesResearch analyst Soumit Roy lowered the firm's price target on Enliven from $36 to $27. Despite the reduction, Roy maintained a Buy rating on the stock, suggesting continued confidence in the company's long-term prospects despite near-term headwinds.While th","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | Enliven Therapeutics Plummets 5.22% as JonesResearch Lowers Price Target","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ELVN"],"gpt_icon":0},{"id":"2536438863","title":"Enliven price target lowered to $27 from $36 at JonesResearch","url":"https://stock-news.laohu8.com/highlight/detail?id=2536438863","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536438863?lang=en_us&edition=fundamental","pubTime":"2025-05-17 00:40","pubTimestamp":1747413629,"startTime":"0","endTime":"0","summary":"JonesResearch analyst Soumit Roy lowered the firm’s price target on Enliven (ELVN) to $27 from $36 and keeps a Buy rating on the shares. The compan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enliven-price-target-lowered-to-27-from-36-at-jonesresearch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enliven-price-target-lowered-to-27-from-36-at-jonesresearch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2536348021","title":"Enliven Therapeutics’ ELVN-001: Promising Competitor in the $3 Billion Late Line CML Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2536348021","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536348021?lang=en_us&edition=fundamental","pubTime":"2025-05-17 00:25","pubTimestamp":1747412748,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Soumit Roy has reiterated their bullish stance on ELVN stock, giving a Buy rating yesterday. Soumit Roy has given his Buy rati...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/enliven-therapeutics-elvn-001-promising-competitor-in-the-3-billion-late-line-cml-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/enliven-therapeutics-elvn-001-promising-competitor-in-the-3-billion-late-line-cml-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","ELVN","BK4139","BK4007","BK4539"],"gpt_icon":0},{"id":"2535221812","title":"Enliven Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $40 From $39","url":"https://stock-news.laohu8.com/highlight/detail?id=2535221812","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535221812?lang=en_us&edition=fundamental","pubTime":"2025-05-15 18:08","pubTimestamp":1747303716,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nAZN3U4PTN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2535001910","title":"Enliven Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2535001910","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535001910?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:35","pubTimestamp":1747254943,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryEnliven Therapeutics Inc ELVN.OQ reported a quarterly adjusted loss of 57 cents per share for the quarter ende","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nL8N3RM2M7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN"],"gpt_icon":0},{"id":"2535114000","title":"Enliven Therapeutics Q1 EPS $(0.57) Misses $(0.49) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535114000","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535114000?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:35","pubTimestamp":1747254926,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.49) by 16.33 percent. This is a 5.56 percent decrease over losses of $(0.54) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45421699/enliven-therapeutics-q1-eps-0-57-misses-0-49-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ELVN"],"gpt_icon":0},{"id":"2535002287","title":"Enliven Therapeutics Q1 Income From Operations USD -31.693 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2535002287","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535002287?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:05","pubTimestamp":1747253104,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nPLX2B68AD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2535007335","title":"Press Release: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535007335","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535007335?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:05","pubTimestamp":1747253100,"startTime":"0","endTime":"0","summary":"Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June. EHA abstract reported cumulative MMR rate of 44%  by 24 weeks with 26%  of patients achieving MMR by 24 weeks, and ELVN-001 remains well-tolerated with 74 patients enrolled. Enliven to host a webcast and conference call following the oral presentation at EHA on Friday, June 13, at 1:30 p.m. ET. Strong balance sheet with $290 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2027. \"We are very pleased with the continued progress of ELVN-001 and the data that was just released in the EHA abstract. We continue to gain confidence and momentum in the program as the efficacy, safety and tolerability data consistently compare favorably to the approved BCR::ABL inhibitors. We are excited to share further updated data at EHA next month,\" said Sam Kintz, Co-founder and Chief Executive Officer of Enliven. \"Looking to","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","ELVN","LENZ","BK4135","BK4539","BK4139","BK4007"],"gpt_icon":0},{"id":"2535077796","title":"Positive Buy Rating for Enliven Therapeutics Driven by Promising Phase 1 Results of ELVN-001 in CML","url":"https://stock-news.laohu8.com/highlight/detail?id=2535077796","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535077796?lang=en_us&edition=fundamental","pubTime":"2025-05-15 00:05","pubTimestamp":1747238728,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics (ELVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky fro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-buy-rating-for-enliven-therapeutics-driven-by-promising-phase-1-results-of-elvn-001-in-cml?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-buy-rating-for-enliven-therapeutics-driven-by-promising-phase-1-results-of-elvn-001-in-cml?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELVN","LENZ"],"gpt_icon":0},{"id":"2535411079","title":"BRIEF-Enliven Therapeutics Says ELVN-001 Shows Favorable Safety And Tolerability Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2535411079","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535411079?lang=en_us&edition=fundamental","pubTime":"2025-05-14 23:04","pubTimestamp":1747235045,"startTime":"0","endTime":"0","summary":"BRIEF-Enliven Therapeutics Says ELVN-001 Shows Favorable Safety And Tolerability ProfileMay 14 (Reuters) - Enliven Therapeutics Inc ELVN.O:ENLIVEN THERAPEUTICS ANNOUNCES UPDATED POSITIVE DATA FROM PHA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUA7P8L9N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2535807837","title":"Enliven Therapeutics Announces Updated Positive Data From Phase 1 Clinical Trial of Elvn-001 in Cml and Oral Presentation at the Eha 2025 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2535807837","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535807837?lang=en_us&edition=fundamental","pubTime":"2025-05-14 21:56","pubTimestamp":1747231003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUA7P8L9N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELVN"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ELVN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-14","symbol":"ELVN","fiscalQuarterEnding":"2025/03","expectedEps":-0.51,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.57},{"market":"US","date":"2025-03-13","symbol":"ELVN","fiscalQuarterEnding":"2024/12","expectedEps":-0.53,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"post","actualEps":-0.46},{"market":"US","date":"2024-11-13","symbol":"ELVN","fiscalQuarterEnding":"2024/09","expectedEps":-0.52,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-0.48},{"market":"US","date":"2024-08-13","symbol":"ELVN","fiscalQuarterEnding":"2024/06","expectedEps":-0.58,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"post","actualEps":-0.41},{"market":"US","date":"2024-05-14","symbol":"ELVN","fiscalQuarterEnding":"2024/03","expectedEps":-0.58,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715659200000,"reportTimeType":"post","actualEps":-0.54}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ELVN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ELVN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.375,"buy":0.625,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.625,"analysts":8,"updateTime":1734148800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ELVN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ELVN","date":"2025-06-06","current":-11.057788,"percent":0.711152,"low":-26.682642,"twenty":-16.804427,"median":-12.734501,"eighty":-10.282309,"high":-6.665619,"avg":-13.700223,"sd":4.386862,"marketCap":1048610043},"quantilePoints":[{"date":"2023-02-24","current":-26.682642,"twenty":-26.682642,"median":-26.682642,"eighty":-26.682642,"marketCap":974023148},{"date":"2023-03-03","current":-24.8289,"twenty":-26.345598,"median":-24.559265,"eighty":-24.199752,"marketCap":906354172},{"date":"2023-03-10","current":-23.694186,"twenty":-25.199648,"median":-24.28963,"eighty":-23.806534,"marketCap":864932556},{"date":"2023-03-17","current":-24.997422,"twenty":-25.053596,"median":-24.508708,"eighty":-23.817768,"marketCap":912505897},{"date":"2023-03-24","current":-25.045524,"twenty":-25.045524,"median":-24.501056,"eighty":-23.817768,"marketCap":943264523},{"date":"2023-03-31","current":-23.847695,"twenty":-25.154418,"median":-24.513309,"eighty":-23.847695,"marketCap":898151871},{"date":"2023-04-06","current":-25.11086,"twenty":-25.119572,"median":-24.513309,"eighty":-23.847695,"marketCap":945725213},{"date":"2023-04-14","current":-20.962015,"twenty":-25.076502,"median":-24.390743,"eighty":-23.811629,"marketCap":789471394},{"date":"2023-04-21","current":-21.332253,"twenty":-25.048753,"median":-24.119928,"eighty":-22.848051,"marketCap":803415304},{"date":"2023-04-28","current":-20.635334,"twenty":-25.016663,"median":-23.926845,"eighty":-21.458569,"marketCap":777167943},{"date":"2023-05-05","current":-20.341321,"twenty":-24.896309,"median":-23.847695,"eighty":-21.260383,"marketCap":766094838},{"date":"2023-05-12","current":-20.851059,"twenty":-24.795534,"median":-23.81078,"eighty":-20.994683,"marketCap":785292584},{"date":"2023-05-19","current":-21.89907,"twenty":-24.705543,"median":-23.593073,"eighty":-21.113722,"marketCap":824762787},{"date":"2023-05-26","current":-21.462399,"twenty":-24.613192,"median":-22.720646,"eighty":-21.211975,"marketCap":808316869},{"date":"2023-06-02","current":-18.734285,"twenty":-24.559265,"median":-21.980633,"eighty":-20.954392,"marketCap":819006716},{"date":"2023-06-09","current":-21.377022,"twenty":-24.515759,"median":-21.83357,"eighty":-20.954392,"marketCap":934539290},{"date":"2023-06-16","current":-18.254642,"twenty":-24.497376,"median":-21.673899,"eighty":-20.758384,"marketCap":798038170},{"date":"2023-06-23","current":-20.812737,"twenty":-24.451411,"median":-21.642525,"eighty":-20.734427,"marketCap":909870413},{"date":"2023-06-30","current":-18.32988,"twenty":-24.28963,"median":-21.616844,"eighty":-20.341321,"marketCap":801327354},{"date":"2023-07-07","current":-17.361189,"twenty":-24.217728,"median":-21.517191,"eighty":-20.09872,"marketCap":758979115},{"date":"2023-07-14","current":-17.135475,"twenty":-24.135893,"median":-21.462399,"eighty":-19.332427,"marketCap":749111564},{"date":"2023-07-21","current":-17.972499,"twenty":-24.119928,"median":-21.435107,"eighty":-18.517975,"marketCap":785703732},{"date":"2023-07-28","current":-16.984999,"twenty":-23.971833,"median":-21.377022,"eighty":-18.220785,"marketCap":742533197},{"date":"2023-08-04","current":-16.881547,"twenty":-23.922067,"median":-21.256028,"eighty":-17.820142,"marketCap":738010570},{"date":"2023-08-11","current":-16.491696,"twenty":-23.861932,"median":-21.016461,"eighty":-17.568094,"marketCap":720967464},{"date":"2023-08-18","current":-12.980214,"twenty":-23.847695,"median":-20.922018,"eighty":-17.248332,"marketCap":669117064},{"date":"2023-08-25","current":-13.578933,"twenty":-23.823753,"median":-20.812737,"eighty":-17.129832,"marketCap":699980398},{"date":"2023-09-01","current":-12.469308,"twenty":-23.815574,"median":-20.736061,"eighty":-17.000046,"marketCap":642780353},{"date":"2023-09-08","current":-12.908368,"twenty":-23.809931,"median":-20.564155,"eighty":-16.862737,"marketCap":665413464},{"date":"2023-09-15","current":-13.123907,"twenty":-23.739125,"median":-20.333094,"eighty":-16.776213,"marketCap":676524264},{"date":"2023-09-22","current":-10.154264,"twenty":-23.633518,"median":-19.996164,"eighty":-15.495828,"marketCap":523442131},{"date":"2023-09-29","current":-10.968521,"twenty":-23.474031,"median":-19.373808,"eighty":-13.527842,"marketCap":565416265},{"date":"2023-10-06","current":-11.511359,"twenty":-23.372472,"median":-19.044642,"eighty":-13.224491,"marketCap":593399020},{"date":"2023-10-13","current":-9.994605,"twenty":-22.593241,"median":-18.52738,"eighty":-13.107941,"marketCap":515211909},{"date":"2023-10-20","current":-10.130315,"twenty":-22.058041,"median":-18.391011,"eighty":-12.999373,"marketCap":522207598},{"date":"2023-10-27","current":-9.555545,"twenty":-22.040989,"median":-18.292261,"eighty":-12.964248,"marketCap":492578798},{"date":"2023-11-03","current":-9.731169,"twenty":-21.920278,"median":-17.972499,"eighty":-12.485274,"marketCap":501632043},{"date":"2023-11-10","current":-7.695346,"twenty":-21.89907,"median":-17.817321,"eighty":-12.245786,"marketCap":475295332},{"date":"2023-11-17","current":-6.952736,"twenty":-21.83357,"median":-17.803213,"eighty":-11.215991,"marketCap":429428758},{"date":"2023-11-24","current":-7.786797,"twenty":-21.720035,"median":-17.492856,"eighty":-10.958941,"marketCap":480943724},{"date":"2023-12-01","current":-7.513225,"twenty":-21.68071,"median":-17.309463,"eighty":-10.760965,"marketCap":464046815},{"date":"2023-12-08","current":-7.506552,"twenty":-21.671453,"median":-17.210713,"eighty":-10.505512,"marketCap":463634696},{"date":"2023-12-15","current":-7.893557,"twenty":-21.652352,"median":-17.121368,"eighty":-10.333081,"marketCap":487537640},{"date":"2023-12-22","current":-8.620858,"twenty":-21.63925,"median":-17.013213,"eighty":-10.031327,"marketCap":532458691},{"date":"2023-12-29","current":-9.721819,"twenty":-21.630859,"median":-16.994403,"eighty":-9.985025,"marketCap":600458446},{"date":"2024-01-05","current":-9.735164,"twenty":-21.621546,"median":-16.919166,"eighty":-9.908649,"marketCap":601282686},{"date":"2024-01-12","current":-7.653347,"twenty":-21.612141,"median":-16.825118,"eighty":-9.735164,"marketCap":472701330},{"date":"2024-01-19","current":-8.547461,"twenty":-21.544748,"median":-16.787499,"eighty":-9.657763,"marketCap":527925374},{"date":"2024-01-26","current":-10.90285,"twenty":-21.510766,"median":-16.702856,"eighty":-9.657763,"marketCap":673403638},{"date":"2024-02-02","current":-10.972911,"twenty":-21.471637,"median":-15.246862,"eighty":-9.711143,"marketCap":677730895},{"date":"2024-02-09","current":-10.282309,"twenty":-21.462504,"median":-13.618847,"eighty":-9.729299,"marketCap":635076503},{"date":"2024-02-16","current":-11.543409,"twenty":-21.454109,"median":-13.399317,"eighty":-9.734365,"marketCap":712967132},{"date":"2024-02-23","current":-10.609261,"twenty":-21.445153,"median":-13.291548,"eighty":-9.761506,"marketCap":655270370},{"date":"2024-03-01","current":-10.655968,"twenty":-21.434015,"median":-13.147855,"eighty":-9.803015,"marketCap":658155208},{"date":"2024-03-08","current":-10.275636,"twenty":-21.409359,"median":-13.10395,"eighty":-9.82474,"marketCap":634664384},{"date":"2024-03-15","current":-6.665619,"twenty":-21.384546,"median":-13.044078,"eighty":-9.733566,"marketCap":477151673},{"date":"2024-03-22","current":-10.431636,"twenty":-21.350161,"median":-12.972231,"eighty":-9.727429,"marketCap":746738233},{"date":"2024-03-28","current":-10.760874,"twenty":-21.310474,"median":-12.880428,"eighty":-9.732767,"marketCap":770306384},{"date":"2024-04-05","current":-12.135517,"twenty":-21.260383,"median":-12.485274,"eighty":-9.752725,"marketCap":868708833},{"date":"2024-04-12","current":-15.541291,"twenty":-21.211975,"median":-12.53879,"eighty":-9.795033,"marketCap":1112507764},{"date":"2024-04-19","current":-11.553574,"twenty":-21.113722,"median":-12.520461,"eighty":-9.82282,"marketCap":827051011},{"date":"2024-04-26","current":-10.971645,"twenty":-20.994683,"median":-12.453342,"eighty":-9.833917,"marketCap":785394226},{"date":"2024-05-03","current":-13.724364,"twenty":-20.956933,"median":-12.42141,"eighty":-9.861485,"marketCap":982444863},{"date":"2024-05-10","current":-15.627075,"twenty":-20.927476,"median":-12.477291,"eighty":-9.897956,"marketCap":1118648510},{"date":"2024-05-17","current":-14.069999,"twenty":-20.877259,"median":-12.55712,"eighty":-9.908649,"marketCap":1119943779},{"date":"2024-05-24","current":-13.579529,"twenty":-20.83573,"median":-12.880428,"eighty":-9.913987,"marketCap":1080903320},{"date":"2024-05-31","current":-13.31952,"twenty":-20.807747,"median":-12.919935,"eighty":-9.925997,"marketCap":1060207172},{"date":"2024-06-07","current":-11.936748,"twenty":-20.777985,"median":-12.852488,"eighty":-9.949337,"marketCap":950141299},{"date":"2024-06-14","current":-13.012238,"twenty":-20.738783,"median":-12.908368,"eighty":-9.978639,"marketCap":1035748089},{"date":"2024-06-21","current":-12.433128,"twenty":-20.734427,"median":-12.823141,"eighty":-9.991412,"marketCap":989652125},{"date":"2024-06-28","current":-13.857265,"twenty":-20.713737,"median":-12.852488,"eighty":-9.999395,"marketCap":1103010568},{"date":"2024-07-05","current":-12.734501,"twenty":-20.635334,"median":-12.852488,"eighty":-10.018554,"marketCap":1013640841},{"date":"2024-07-12","current":-14.217731,"twenty":-20.492975,"median":-12.947875,"eighty":-10.03452,"marketCap":1131702953},{"date":"2024-07-15","current":-14.619562,"twenty":-20.462644,"median":-12.964248,"eighty":-10.034701,"marketCap":1163687908},{"date":"2024-08-02","current":-14.595925,"twenty":-20.432313,"median":-12.972231,"eighty":-10.034882,"marketCap":1161806440},{"date":"2024-08-09","current":-12.834959,"twenty":-20.33803,"median":-12.964248,"eighty":-10.054109,"marketCap":1021637080},{"date":"2024-08-16","current":-13.556309,"twenty":-20.306761,"median":-12.945278,"eighty":-10.088634,"marketCap":1122828410},{"date":"2024-08-23","current":-13.060138,"twenty":-20.227193,"median":-12.964248,"eighty":-10.111156,"marketCap":1081732040},{"date":"2024-08-30","current":-12.672326,"twenty":-20.030349,"median":-12.961651,"eighty":-10.130701,"marketCap":1049610739},{"date":"2024-09-06","current":-12.495529,"twenty":-19.786892,"median":-12.919935,"eighty":-10.135876,"marketCap":1034967205},{"date":"2024-09-13","current":-12.73506,"twenty":-19.581572,"median":-12.931502,"eighty":-10.154517,"marketCap":1054806832},{"date":"2024-09-20","current":-13.157091,"twenty":-19.368165,"median":-12.8873,"eighty":-10.156457,"marketCap":1089762365},{"date":"2024-09-27","current":-13.755918,"twenty":-19.332427,"median":-12.959054,"eighty":-10.16247,"marketCap":1139361432},{"date":"2024-10-04","current":-14.548651,"twenty":-19.185713,"median":-12.995005,"eighty":-10.191351,"marketCap":1205021150},{"date":"2024-10-11","current":-15.381306,"twenty":-18.794475,"median":-13.012238,"eighty":-10.271051,"marketCap":1273987472},{"date":"2024-10-18","current":-15.980134,"twenty":-18.692904,"median":-13.06278,"eighty":-10.276971,"marketCap":1323586540},{"date":"2024-10-25","current":-16.527633,"twenty":-18.517975,"median":-13.077247,"eighty":-10.282309,"marketCap":1368934258},{"date":"2024-10-31","current":-16.191149,"twenty":-18.480356,"median":-13.117169,"eighty":-10.282309,"marketCap":1341064306},{"date":"2024-11-08","current":-16.539039,"twenty":-18.452142,"median":-13.127899,"eighty":-10.308998,"marketCap":1369879003},{"date":"2024-11-15","current":-14.288385,"twenty":-18.32988,"median":-13.147855,"eighty":-10.377785,"marketCap":1217570416},{"date":"2024-11-22","current":-14.569336,"twenty":-18.254642,"median":-13.191309,"eighty":-10.377785,"marketCap":1241511408},{"date":"2024-11-29","current":-13.978765,"twenty":-18.119213,"median":-13.257473,"eighty":-10.420866,"marketCap":1191186467},{"date":"2024-12-06","current":-13.330857,"twenty":-17.99507,"median":-13.275582,"eighty":-10.465191,"marketCap":1135975609},{"date":"2024-12-13","current":-13.187514,"twenty":-17.927356,"median":-13.313517,"eighty":-10.47358,"marketCap":1123760818},{"date":"2024-12-20","current":-13.112976,"twenty":-17.840832,"median":-13.307514,"eighty":-10.475365,"marketCap":1117409126},{"date":"2024-12-27","current":-13.021237,"twenty":-17.81638,"median":-13.27352,"eighty":-10.487821,"marketCap":1109591659},{"date":"2025-01-03","current":-13.703547,"twenty":-17.808856,"median":-13.27352,"eighty":-10.502895,"marketCap":1167734067},{"date":"2025-01-10","current":-13.84689,"twenty":-17.803213,"median":-13.275582,"eighty":-10.521478,"marketCap":1179948858},{"date":"2025-01-17","current":-12.60841,"twenty":-17.759951,"median":-13.27352,"eighty":-10.564579,"marketCap":1074413060},{"date":"2025-01-24","current":-12.637079,"twenty":-17.586904,"median":-13.268745,"eighty":-10.609261,"marketCap":1076856018},{"date":"2025-01-31","current":-12.195584,"twenty":-17.492856,"median":-13.225528,"eighty":-10.642623,"marketCap":1039234460},{"date":"2025-02-07","current":-12.883628,"twenty":-17.445832,"median":-13.157091,"eighty":-10.649204,"marketCap":1097865460},{"date":"2025-02-14","current":-12.327459,"twenty":-17.361189,"median":-13.147855,"eighty":-10.655968,"marketCap":1050472069},{"date":"2025-02-21","current":-12.310258,"twenty":-17.278427,"median":-13.123907,"eighty":-10.661306,"marketCap":1049006294},{"date":"2025-02-28","current":-11.553409,"twenty":-17.220118,"median":-13.115073,"eighty":-10.671914,"marketCap":984512194},{"date":"2025-03-07","current":-12.304524,"twenty":-17.210713,"median":-13.077247,"eighty":-10.692528,"marketCap":1048517702},{"date":"2025-03-14","current":-11.168896,"twenty":-17.203189,"median":-13.06278,"eighty":-10.70156,"marketCap":994299783},{"date":"2025-03-21","current":-11.515688,"twenty":-17.148642,"median":-13.044078,"eighty":-10.73075,"marketCap":1025172571},{"date":"2025-03-28","current":-11.840461,"twenty":-17.112904,"median":-13.012192,"eighty":-10.756253,"marketCap":1054085181},{"date":"2025-04-04","current":-11.025775,"twenty":-17.062118,"median":-12.992568,"eighty":-10.756253,"marketCap":981558632},{"date":"2025-04-11","current":-8.207404,"twenty":-17.020737,"median":-12.961651,"eighty":-10.671914,"marketCap":730655976},{"date":"2025-04-17","current":-8.845942,"twenty":-17.00757,"median":-12.919935,"eighty":-10.646572,"marketCap":787501109},{"date":"2025-04-25","current":-10.073474,"twenty":-16.992523,"median":-12.900829,"eighty":-10.506428,"marketCap":896780977},{"date":"2025-05-02","current":-10.926692,"twenty":-16.945499,"median":-12.87493,"eighty":-10.47358,"marketCap":972737836},{"date":"2025-05-09","current":-10.268015,"twenty":-16.896595,"median":-12.837758,"eighty":-10.456802,"marketCap":914099729},{"date":"2025-05-16","current":-9.22086,"twenty":-16.864245,"median":-12.824716,"eighty":-10.419165,"marketCap":874414177},{"date":"2025-05-23","current":-8.677544,"twenty":-16.841798,"median":-12.774982,"eighty":-10.35027,"marketCap":822891456},{"date":"2025-05-30","current":-9.179465,"twenty":-16.826999,"median":-12.740411,"eighty":-10.284647,"marketCap":870488636},{"date":"2025-06-06","current":-11.057788,"twenty":-16.804427,"median":-12.734501,"eighty":-10.282309,"marketCap":1048610043}],"updateTime":1749392628177}}}